Skip to content

Changes in visual function and refractive progression in children in the pre-myopia stage who use 0.01% atropine eye drops in combination with flipper training

Changes in visual function and refractive progression in children in the pre-myopia stage who use 0.01% atropine eye drops in combination with flipper training

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105018
Enrollment
Unknown
Registered
2025-06-26
Start date
2025-07-05
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-myopia stage

Interventions

The experimental group (atropine combined with flipper training group):atropine combined with flipper training
The control group (atropine used alone group):Use atropine alone

Sponsors

Eye Hospital, Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1.The age is between 6 and 12 years old; 2.The binocular spherical equivalent refraction under cycloplegia: +0.75D to -0.50D; 3.The astigmatism is less than 1.0 diopter (D); 4.The anisometropia is less than 1.0 diopter (D); 5.The best corrected visual acuity of a single eye: logMAR <= 0.00; 6.There are axial length data for three months or more, and the average axial length growth in the recent three months is greater than 0.1mm; 7.The binocular accommodation amplitude reaches the minimum accommodation amplitude corresponding to one's own age;

Exclusion criteria

Exclusion criteria: 1. Using myopia prevention and control products for more than one month within one year; 2. History of ophthalmic surgery; 3. History of eye diseases (such as amblyopia, strabismus, glaucoma, etc.); 4. Contraindications to atropine (such as a history of atropine allergy, intraocular pressure >= 21 mmHg or the difference in intraocular pressure between the two eyes >= 5 mmHg, 5. The peripheral anterior chamber depth <= 1/4 of the corneal thickness); 6. Poor overall health status (such as heart or respiratory diseases);

Design outcomes

Primary

MeasureTime frame
Accommodation facility;

Countries

China

Contacts

Public ContactJingjing Xu

Eye Hospital, Wenzhou Medical University

xujj@eye.ac.cn+86 577 8806 8166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026